Pediatric Drugs

, Volume 15, Issue 5, pp 351–362 | Cite as

Management of Diffuse Pontine Gliomas in Children: Recent Developments

Review Article


The prognosis for children with diffuse intrinsic pontine gliomas (DIPGs) is dismal. Although DIPGs constitute only 10–15 % of all pediatric brain tumors, they are the main cause of death in this group with a median survival of less than 12 months. Standard therapy involves radiotherapy, which produces transient neurologic improvement. Despite several clinical trials having been conducted, including trials on targeted agents to assess their efficacy, there is no clear improvement in prognosis. However, knowledge of DIPG biology is increasing, mainly as a result of research using biopsy and autopsy samples. In this review, we discuss recent studies in which systemic therapy was administered prior to, concomitantly with, or after radiotherapy. The discussion also includes novel therapeutic options in DIPG. Continuing multimodal and multitargeted therapies might lead to an improvement in the dismal prognosis of the disease.


  1. 1.
    Fleming AJ, Chi SN. Brain tumors in children. Curr Probl Pediatr Adolesc Health Care. 2012;42:80–103.PubMedCrossRefGoogle Scholar
  2. 2.
    Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumors in Europe. Eur J Cancer. 2012;48:1532–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Choux M, Lena G, Do L. Brainstem tumors. In: Choux M, Di Rocco C, Hockley A, editors. Pediatric neurosurgery. New York: Churchill Livingstone; 2000. p. 471–91.Google Scholar
  4. 4.
    Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Phys. 1998;40:265–71.CrossRefGoogle Scholar
  5. 5.
    Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Jennings MT, Freeman ML, Murray MJ. Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J Neurooncol. 1996;28:207–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Jennings M, Spotso R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol. 2002;20:3431–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Kretschmar CS, Tarbell NJ, Barnes PD, et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors: a phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer. 1993;72:1404–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Dunkel IJ, Garvin JH Jr, Goldman S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children’s Cancer Group. J Neurooncol. 1998;37:67–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Frappaz D, Schell M, Thiesse P, et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol. 2008;10(4):599–607.PubMedCrossRefGoogle Scholar
  11. 11.
    Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol. 2008;87:355–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Grundy RG, Wilne SH, Robinson KJ, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer. 2010;46(1):120–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Wolff JE, Kortmann RD, Wolff B, et al. High dose methotrexate for pediatric high grade glioma—results of the HIT-GBM-D Pilot study. J Neurooncol. 2011;102:433–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Doz F, Neuenschwander S, Bouffet E, Gentet JC, Schneider P, Kalifa C, et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d’Oncologie Pédiatrique. Eur J Cancer. 2002;38:815–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Bernier-Chastagner V, Grill J, Doz F, et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology phase II study. Cancer. 2005;104:2792–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Packer RJ, Krailo M, Mehta M, et al. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104:1281–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolff JE, Westphal S, Molenkamp G, et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer. 2002;87:945–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79(3):315–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116(3):705–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79:281–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005;103:133–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20:4684–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77:113–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Chiang KL, Chang KP, Lee YY, et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst. 2010;26:1035–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Kim CY, Kim SK, Phi JH, et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol. 2010;100:193–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Chassot A, Canale S, Varlet P, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012;106:399–407.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen K, Heideman R, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 2011;4:410–6.CrossRefGoogle Scholar
  30. 30.
    Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Sirachainan N, Pakakasama S, Visudithbhan A, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol. 2008;10:577–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Kebudi R, Cakir FB, Yaman Agaoglu F, et al. Pediatric diffuse intrinsic pontine glioma patients from a single center. Childs Nerv Syst. 2013;29(4):583–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12:985–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069–75.PubMedCrossRefGoogle Scholar
  36. 36.
    Stockhammer G. Avastin/irinotecan in patients with recurrent or progressive malignant glioma (AVIRMA01-09). identifier NCT01144988. Accessed May 16 2013.
  37. 37.
    Cruz O, de Torres C, Suñol M, Salvador H, Lopez E, Cardesa T, et al. Multimodal therapy for diffuse intrinsic pontine gliomas including nimotuzumab and bevacizumab [abstract no. DIPG.08]. Neuro Oncol. 2010;12(6):ii10.Google Scholar
  38. 38.
    Kieran MW. Molecularly determined treatment of diffuse intrinsic pontine gliomas (DIPG). identifier NCT01182350. Accessed May 16 2013.
  39. 39.
    Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007;82:95–101.PubMedCrossRefGoogle Scholar
  40. 40.
    Kivivuori SM, Riikonen P, Valanne L, Lonnqvist T, Saarinen-Pihkala UM. Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta Paediatr. 2011;100(1):134–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Pediatric Brain Tumor Consortium. Enzastaurin in treating young patients with refractory primary CNS tumors. identifier NCT00503724. Accessed 30 Sep 2010.
  42. 42.
    Pediatric Brain Tumor Consortium, National Cancer Institute. AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. identifier NCT00326664. Accessed 25 Jan 2011.
  43. 43.
    Gilbertson RJ, Ashley H, Herman R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Can Res. 2003;9:3620–4.Google Scholar
  44. 44.
    Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents [abstract]. J Clin Oncol 2007; 25(Suppl. 2006).Google Scholar
  45. 45.
    Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011;11(2):247–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Massimino M, Biassoni V, Gandola L, et al. Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: promising results on a series of 20 patients [abstract no. PG-04]. Pediatr Blood Cancer. 2012;59:1004.Google Scholar
  47. 47.
    Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15:701–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Geoerger B, Hargrave D, Thomas F, et al. ITCC (Innovative Therapies for Children with Cancer) European Consortium. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.PubMedCrossRefGoogle Scholar
  49. 49.
    Geyer JR, Stewart CF, Kocak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Broniscer A. Clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). identifier NCT00996723. Accessed May 16 2013.
  53. 53.
    Memorial Sloan-Kettering Cancer Center. External beam radiation therapy and cetuximab followed by irinotecan and cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas (POE08-01). identifier NCT01012609. Accessed 30 Sep 2010.
  54. 54.
    Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298–306.PubMedCrossRefGoogle Scholar
  56. 56.
    Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011;104(1):179–89.PubMedCrossRefGoogle Scholar
  57. 57.
    Insys Therapeutics Inc. The PRECISE trial: study of IL13-PE38QQR compared to GLIADEL wafer in patients with recurrent glioblastoma multiforme. identifier NCT00076986. Accessed May 16 2013.
  58. 58.
    Lonser RR, Warren KE, Butman JA, et al. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg. 2007;107(1):190–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.PubMedCrossRefGoogle Scholar
  60. 60.
    Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712–8.PubMedCrossRefGoogle Scholar
  61. 61.
    MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium study PBTC-012. J Clin Oncol. 2008;26:919–24.PubMedCrossRefGoogle Scholar
  62. 62.
    Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515–25.PubMedCrossRefGoogle Scholar
  63. 63.
    Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54:519–25.PubMedGoogle Scholar
  64. 64.
    Phuphanich S. Immunotherapy for patients with brain stem glioma and glioblastoma. identifier NCT00576641. Accessed May 16 2013.
  65. 65.
    Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437–42.PubMedGoogle Scholar
  66. 66.
    Felix FH, Trompieri NM, de Araujo OL, et al. Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol. 2011;28(7):556–70.PubMedCrossRefGoogle Scholar
  67. 67.
    Children’s Oncology Group, National Cancer Institute. Vorinostat and radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed pontine glioma. identifier NCT01189266. Accessed 30 Sep 2010.
  68. 68.
    Lee EQ, Puduvalli VK, Reid JM, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04–03. Clin Cancer Res. 2012;18(21):6032–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Zeng WF, Navaratne K, Prayson RA, et al. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol. 2007;60:218–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18:379–98.PubMedCrossRefGoogle Scholar
  71. 71.
    Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors: rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9:268–78.PubMedCrossRefGoogle Scholar
  72. 72.
    Buczkowicz P, Zarghooni M, Bartels U, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol. 2013;23(3):244–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353–63.PubMedCrossRefGoogle Scholar
  74. 74.
    Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011;29(26):3529–34.PubMedCrossRefGoogle Scholar
  75. 75.
    Pediatric Brain Tumor Consortium, National Cancer Institute. ABT-888 and temozolomide in treating young patients with recurrent or refractory CNS tumors. Accessed 25 Jan 2011.
  76. 76.
    Barth RF, Vicente M, Harling OK, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7(146):1–21.Google Scholar
  77. 77.
    Sköld K, Gorlia T, Pellettieri L, et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol. 2010;83(991):596–603.PubMedCrossRefGoogle Scholar
  78. 78.
    Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J Neurooncol. 2003;62(1–2):101–9.PubMedGoogle Scholar
  79. 79.
    Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y. Clinical results of BNCT for malignant brain tumors in children. Appl Radiat Isot. 2009;67(7–8 Suppl):S27–30.PubMedCrossRefGoogle Scholar
  80. 80.
    Wolff JE, Rytting ME, Vats TS, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106:391–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Jenkin RD, Boesel C, Ertel I, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66:227–33.PubMedCrossRefGoogle Scholar
  82. 82.
    Jakacki RI, Jamison C, Mathews VP, et al. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. Med Pediatr Oncol. 1998;31:483–90.PubMedCrossRefGoogle Scholar
  83. 83.
    Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol. 1998;30:28–33.PubMedCrossRefGoogle Scholar
  84. 84.
    Allen J, Siffert J, Donahue B, et al. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer. 1999;86:1064–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000;88:685–92.PubMedCrossRefGoogle Scholar
  86. 86.
    Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227–30.PubMedCrossRefGoogle Scholar
  87. 87.
    Michalski A, Bouffet E, Taylor RE, et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol. 2010;100(1):81–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Istanbul University Cerrahpasa Medical Faculty Pediatric Hematology-OncologyIstanbulTurkey
  2. 2.Istanbul University Oncology Institute Pediatric Hematology-OncologyIstanbulTurkey
  3. 3.Bezmialem Vakif University Medical Faculty Department of Pediatric Hematology-OncologyIstanbulTurkey

Personalised recommendations